DPP3 Threshold Monitoring for Early Septic Shock Intervention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to accurately predict and prevent the short-term increase of Dipeptidyl peptidase 3 (DPP3) levels in critically ill patients, particularly those with septic shock, leading to potential organ dysfunction and increased mortality, as current thresholds for intervention are not sensitive enough to identify patients at risk.
Innovation Solution
A method for predicting DPP3 increase by determining its levels in bodily fluids and comparing them to a threshold between 40 ng/ml and 22 ng/ml, indicating a likely short-term rise, allowing for targeted therapy with DPP3 inhibitors or anti-ADM antibodies based on DPP3 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current threshold methods are used to monitor DPP3 levels, then the monitoring process is simple, but the prediction accuracy of DPP3 increase is insufficient
Solution Approach 1:
The patent applies parameter changes by establishing a dynamic threshold system that adapts to individual patient baseline DPP3 levels. Instead of using fixed thresholds, the system calculates patient-specific thresholds based on baseline measurements and monitors deviations from these personalized parameters, thereby improving prediction accuracy while maintaining manageable complexity through automated calculations.
Solution Approach 2:
The patent implements feedback mechanisms by continuously monitoring DPP3 levels and comparing them against dynamically adjusted thresholds. When DPP3 levels exceed the threshold, the system triggers alerts and can initiate preventive treatments. This closed-loop feedback system enhances prediction accuracy by learning from historical data and adjusting thresholds over time, while the automated nature of the feedback reduces operational complexity.
2Reliability
If intervention thresholds are set higher, then fewer patients are treated, but more patients with organ dysfunction are missed
Solution Approach 1:
The patent changes the parameter of intervention thresholds from fixed high values to dynamic, patient-specific thresholds based on baseline DPP3 levels and individual risk factors. This allows the system to identify at-risk patients earlier in their disease course, improving reliability of patient outcomes by preventing organ dysfunction before it occurs, while maintaining treatment efficiency through targeted intervention only when necessary.
Solution Approach 2:
The patent applies preliminary action by initiating preventive treatments before organ dysfunction actually occurs. By monitoring DPP3 levels against dynamic thresholds and intervening when thresholds are exceeded but before clinical deterioration happens, the system improves patient outcomes through early prevention while avoiding unnecessary treatments by waiting for objective threshold violations rather than treating all patients prophylactically.
3Measurement precision
If DPP3 levels are monitored frequently, then early detection of increase is improved, but resource consumption increases
Solution Approach 1:
The patent applies dynamics by implementing adaptive monitoring frequencies that adjust based on patient risk status and DPP3 level trends. High-risk patients with baseline DPP3 levels near their thresholds undergo more frequent monitoring, while stable low-risk patients are monitored less frequently. This dynamic approach improves detection sensitivity for those who need it most while reducing overall resource consumption by avoiding unnecessary frequent measurements in stable patients.
Solution Approach 2:
The patent changes the monitoring frequency parameter from fixed to variable based on individual patient needs. The system adjusts monitoring intervals dynamically according to baseline DPP3 levels, rate of change, and proximity to intervention thresholds, thereby optimizing the balance between detection sensitivity and resource utilization for each patient individually.
Data Source
AI summary
The invention relates to a method for the prediction of an increase of dipeptidyl peptidase 3 (DPP3) in a critically ill patient. In particular, the method comprises providing a sample from said patient, determining a level of Dipeptidyl peptidase 3 (DPP3) in said sample, comparing said level to a pre-determined threshold, wherein the level of DPP3 in said sample is indicative of an increase of DPP3 if said level of DPP3 is above a pre-determined threshold level, which is in the range between 22 and 40 ng/ml. Furthermore, the invention also relates to a method for the prevention of a DPP3 increase in a critical ill patient, wherein a DPP3 inhibitor is administered to the patient if the level of DPP3 is above a threshold between 40 ng/ml and 22 ng/ml and said DPP3 inhibitor is an anti-DPP3-antibody and/or and anti-DPP3-antibody fragment and/or anti-DPP3 scaffold. Moreover, the invention also relates to a DPP3 inhibitor for use in the prevention of a DPP3 increase in a critical ill patient.